Kiniksa Pharmaceuticals International (MEX:KNSAN) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:KNSAN Kiniksa Pharmaceuticals International PLC MEX:KNSAN
50 GF Score
Price MXN754.37
GF Value MXN601.54
! 4 Warning Signs
View Full Analysis

What is Kiniksa Pharmaceuticals International Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

MEX:KNSAN
50GF Score
Kiniksa Pharmaceuticals International PLC MEX:KNSAN
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Kiniksa Pharmaceuticals International (MEX:KNSAN) Overvalued in 2026?

Based on GuruFocus' analysis, Kiniksa Pharmaceuticals International stock appears to be overvalued. The current stock price of MXN754.37 is trading 25.4% above its estimated GF Value™ of MXN601.54.

Key valuation signals for MEX:KNSAN:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: MXN601.54 vs. price of MXN754.37 (25.4% above fair value)
  • GF Score™: 50/100 with 4 warning signs

No single metric tells the full story. See the MEX:KNSAN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kiniksa Pharmaceuticals International Business Description

Other Exchanges KNSA:USA
Address 105 Piccadilly, Second Floor, London, GBR, W1J 7NJ
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
50GF Score

Get the complete analysis for MEX:KNSAN

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN754.37
Price
MXN601.54
GF Value